Is liver-targeted FOXp3 staining beneficial after living-donor liver transplantation?

Transplant Infectious Disease

Volumn 14, Issue 2, 2012, Pages 156-162

  Eguchi, S ^a   Hidaka, M ^a   Soyama, A ^a   Takatsuki, M ^a   Miyaaki, H ^a   Ichikawa, T ^a   Nakao, K ^a   Kanematsu, T ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Acute cellular rejection; CD25; FOXp3; Living donor liver transplantation; Recurrent hepatitis C

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; FEMALE; HEPATITIS ACTIVITY INDEX; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; REJECTION ACTIVITY INDEX; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; BIOLOGICAL MARKERS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; STAINING AND LABELING; T-LYMPHOCYTES;

EID: 84859811961     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00690.x     Document Type: Article

References (24)

1. Eguchi S, Takatsuki M, Soyama Y, et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. Ann Transplant 2007; 12 (4): 11-15.
2. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10 (10): 1233-1239.
3. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
4. Piccirillo CA, Thornton AM. Cornerstone of peripheral tolerance: naturally occurring CD4+ CD25+ regulatory T cells. Trends Immunol 2004; 25 (7): 374-380.
5. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004; 114 (9): 1198-1200.
6. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
7. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2 (9): 816-822.
8. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6 (8): 745-751.
9. Coutinho A, Hori S, Carvalho T, Caramalho I, Demengeot J. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and 'quality control' of immune responses. Immunol Rev 2001; 182: 89-98.
10. Lan RY, Ansari AA, Lian ZX, Gershwin ME Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005; 4 (6): 351-363.
11. Furuno K, Yuge T, Kusuhara K, et al. CD25+ CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr 2004; 145 (3): 385-390.
12. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109 (1): 131-140.
13. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6 (4): 345-352.
14. Miyaaki H, Zhou H, Ichikawa T, et al. Study of liver-targeted regulatory T cells in hepatitis B and C virus in chronically infected patients. Liver Int 2009; 29 (5): 702-707.
15. Demirkiran A, Baan CC, Kok A, Metselaar HJ, Tilanus HW, van der Laan LJ. Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation 2007; 83 (6): 819-823.
16. Brown K, Wong W. Diagnostic value of regulatory T cells: a new facet of a much studied cell population. Transplantation 2008; 86 (11): 1485-1491.
17. Perrella A, Arenga G, Pisaniello D, et al. Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplant Proc 2009; 41 (5): 1761-1766.
18. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1 (5): 431-435.
19. [Anonymous.] Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25 (3): 658-663.
20. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for histopathological staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31 (3): 792-799.
21. Jain A, Ryan C, Mohanca R, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant. Clin Transplant 2006; 20 (5): 624-633.
22. Fehervari Z, Sakaguchi S. CD4+ tregs and immune control. J Clin Invest 2004; 114 (9): 1209-1217.
23. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174 (4): 1783-1786.
24. Sakamoto R, Asonuma K, Zeledon Ramirez ME, Yoshimoto K, Nishimori A, Inomata Y. Forkhead box P3 (FOXP3) mRNA expression immediately after living-donor liver transplant. Exp Clin Transplant 2009; 7 (1): 8-12.